Elephas Biosciences Secures $40M Series B-2 Funding to Launch Live Tumor Profiling Platform for Immunotherapy Response Prediction
核心洞察
Elephas Biosciences (搜索) raised $40 million in Series B-2 funding from existing investors to commercialize its live tumor profiling platform for predicting immunotherapy responses.
The Elephas Live™ Platform will launch as a laboratory developed test in 2026, using ex vivo live tumor biopsies to preserve the native tumor microenvironment.
The technology addresses the critical challenge that only 1 in 5 patients receiving immunotherapy obtain a response due to lack of accurate predictive biomarkers.
Elephas Biosciences (搜索) Corporation announced the completion of a $40 million Series B-2 funding round to accelerate commercialization of its innovative live tumor profiling platform designed to predict immunotherapy response rates. The Madison, Wisconsin-based company secured reinvestment from existing backers including Northpond Ventures (搜索), ARCH Venture Partners (搜索), the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital, and Venture Investors Health Fund.
The funding will support the launch of the proprietary Elephas Live™ Platform as a laboratory developed test (LDT) scheduled for 2026. This technology represents a significant advancement in addressing one of oncology's most pressing challenges: the inability to accurately predict which patients will respond to immunotherapy treatments.
Addressing Critical Unmet Medical Need
Cancer represents a leading cause of death worldwide, with patient numbers projected to triple by 2060. Despite the significant increase in available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response. Many patients who may potentially respond are not eligible for therapy due to the lack of accurate predictive biomarkers.
"This financing milestone underscores the strong investor confidence in the promise of Elephas and our shared mission to improve the lives of those affected by cancer," said Maneesh Arora, Elephas founder and CEO. "We have made incredible progress this year and have strong momentum heading into 2026. This funding achievement will drive our next stage of growth and advance our commercialization strategy."
Innovative Technology Platform
The Elephas Live Platform is designed to functionally profile ex vivo live tumor biopsies by protecting the native tumor microenvironment. The technology employs a novel method to address tumor heterogeneity, enabling prediction of immunotherapy response through real-time characterization of immune response from live core needle biopsies.
This approach preserves the complex interactions within the tumor microenvironment that are critical for understanding how a patient's immune system will respond to immunotherapy treatments. By maintaining these native conditions, the platform aims to provide more accurate predictions than current biomarker approaches.
Scientific Leadership and Industry Recognition
Elephas recently strengthened its scientific advisory capabilities by welcoming Jérôme Galon, Ph.D., to the company's expanding Scientific Advisory Board. Dr. Galon, along with fellow advisory board member Janis Taube, M.D., will represent Elephas at the upcoming Societies for the Immunotherapy in Cancer (SITC) Annual Meeting on November 8, 2025, in National Harbor, Maryland, for a symposium focused on improved prediction of immunotherapy response.
The company's participation in this prestigious scientific meeting underscores the clinical relevance and potential impact of its technology platform within the immunotherapy research community.
Commercial Strategy and Market Position
The Series B-2 funding positions Elephas to execute its commercialization strategy for the Elephas Live Platform as an LDT in 2026. XMS Capital Partners served as financial advisor to the company during this funding round, facilitating the successful completion of the equity raise.
The reinvestment from existing investors demonstrates continued confidence in Elephas' predictive approach to improving immunotherapy treatment response rates. This financial backing provides the company with the resources necessary to advance through the final stages of platform development and prepare for market launch.